The author opens by framing a long-standing regulatory and public-health problem in the United States: clinics and firms offering unproven stem cell and other cellular products that are not approved by the Food and Drug Administration. The source highlights that this is a pervasive commercial sector that has drawn ongoing scrutiny and skepticism from scientists and regulators.
The article recounts that in June 2025, Robert F. Kennedy Jr., then recently appointed as health secretary, disclosed on a podcast that he had received unproven stem cell treatments in the Caribbean to address a throat condition. The author states that this disclosure initially raised concern that clinics selling questionable stem cell treatments in the U.S. might escape FDA scrutiny under the new administration. The anecdote is used to set the stage for the author’s initial worry about future regulatory enforcement.
The piece cites a research paper as providing the best estimate available for the size of the market for unproven cellular therapies in the U.S. That paper counted clinics some years ago and estimated there are more than 2,000 firms across the country marketing non-FDA-approved cellular products. This figure is presented as an indicator of the scale and scope of the regulatory challenge.
Contrary to the author’s earlier concerns, the article reports that the FDA—specifically its biologics branch—has taken notable enforcement steps against the problem of unproven stem cell clinics. The author characterizes these developments as two “big fronts” where the agency has acted and describes the FDA’s approach as science-based. The piece calls these actions a surprising bright spot and suggests they merit discussion and cautious celebration.
Note on specifics: The provided source is truncated and labeled STAT+ exclusive. The full descriptions of the two recent FDA actions, including which firms or clinics were targeted, the exact regulatory instruments used (for example, warning letters, import alerts, injunctions, or other measures), dates, and any immediate outcomes, were not included in the accessible portion of the article. Therefore, precise operational details and examples cannot be reported here because they were not present in the supplied source text.
The author emphasizes the broader significance of the FDA’s enforcement in the context of an environment where medical regulation can be influenced by ideological or political pressures. By describing the agency’s responses as “science-based successes,” the author asserts that such regulatory activity is especially noteworthy when political dynamics might otherwise push toward deregulation or inconsistent enforcement. The implication is that robust regulatory oversight for cellular therapies remains important to protect patients and uphold scientific standards.
Readers should be aware that the source text provided here is incomplete. The original piece appears as an opinion column on STAT and is partly behind a STAT+ paywall. As a result, the specific nature of the FDA’s two actions, the names or number of clinics affected, any legal or regulatory rationale offered by the agency, follow-on enforcement steps, and commentary from stakeholders are not reported in the excerpt available for this summary. The author’s fuller arguments, supporting evidence, and any recommendations are likewise not accessible from the truncated source.
The author is Paul Knoepfler, a professor of cell biology and human anatomy at UC Davis School of Medicine, who writes a Lab Dish opinion column for STAT. The article was published on Sept. 3, 2026, and is presented as a STAT+ exclusive. The framing of the piece is opinionated but grounded in concerns about clinical and regulatory standards for cellular products.
If you need a deeper, source-based account of the exact FDA actions referenced, the names of targeted clinics or firms, or the author’s detailed analysis, those specifics were not reported in the available excerpt and would require access to the full STAT+ article.